Tower Research Capital LLC (Trc) Cerevel Therapeutics Holdings, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 33,086 shares of CERE stock, worth $0. This represents 0.02% of its overall portfolio holdings.
Number of Shares
33,086
Previous 728
4444.78%
Holding current value
$0
Previous $30,000
4406.67%
% of portfolio
0.02%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CERE
# of Institutions
242Shares Held
154MCall Options Held
2.19MPut Options Held
3.87M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...